Stock Analiz

Pluri Inc. PLUR

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$1.05Market cap $15M
Open the interactive analysis →

Pluri Inc. (PLUR) is a healthcare company listed in the US with a market value of about $15M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$28M, a net margin of -1943.9%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -55%.

About Pluri

Pluri is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $379000 in 2015 to $1M in 2026, growth of about 9.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 113% over three years (dilution for shareholders). It spends 1485% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S10.3
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-127.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-23.9%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-7587.0%
ROIC (5-yr avg.)-54.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$1M$1M$1M$326000$287000$234000—$23000$54000$50000—
Net income-$28M-$24M-$23M-$21M-$28M-$41M-$50M-$29M-$35M-$26M-$28M
Free cash flow-$19M-$20M-$20M-$18M-$23M-$37M-$31M-$27M-$30M-$22M-$22M
EPS (diluted)$-2.33$-2.44$-3.56$-3.99$-6.24$-10.24$-14.16$-12.80$-23.20$-20.00$-25.60
Net margin-1943.9%-2344.6%-1690.3%-6407.4%-9867.9%-17624.8%—-126700.0%-65383.3%-52252.0%—
ROIC———-58.9%-49.8%-55.8%-48.9%-39.5%-128.6%-93.5%-73.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Pluri pay a dividend?

Not currently.

Is Pluri a good stock to buy?

We do not give buy or sell advice. Pluri scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.